PDCD1 and non-small cell lung carcinoma: The KEYNOTE-024 (2) used ICIs for the advanced NSCLC and confirmed the superiority of first-line programmed cell death protein-1(PD-1) inhibitor monotherapy over conventional chemotherapy in ≥ 50% PD-L1-positive NSCLC patients.